GZ419829
Drug
GENZYME CORPORATION
Total Payments
$89,047
Transactions
53
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $84,991 | 41 | 0 |
| 2018 | $2,042 | 5 | 0 |
| 2017 | $2,014 | 7 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $89,047 | 53 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Prospective Safety Sub-Registry to Assess Anaphylaxis and Severe Allergic Reactions, and Severe Cutaneous and Systemic Immune Complex Mediated Reactions With Alglucosidase Alfa Treatment | GENZYME CORPORATION | $71,112 | 0 |
| A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa. | GENZYME CORPORATION | $13,879 | 0 |
| A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa. | SANOFI US SERVICES INC. | $3,670 | 0 |
| A Prospective Safety Sub-Registry to Assess Anaphylaxis and Severe Allergic Reactions, and Severe Cutaneous and Systemic Immune Complex Mediated Reactions With Alglucosidase Alfa Treatment | SANOFI US SERVICES INC. | $250.00 | 0 |
| A Long-term Study to Evaluate Growth and Development Outcomes in Patients with Infantile-Onset Pompe Disease Who Are Receiving Myozyme? (alglucosidase alfa) | SANOFI US SERVICES INC. | $136.77 | 0 |
Top Doctors Receiving Payments for GZ419829
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Detroit, MI | $89,047 | 53 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $84,991
- SANOFI US SERVICES INC. $4,056
Product Information
- Type Drug
- Total Payments $89,047
- Total Doctors 0
- Transactions 53
About GZ419829
GZ419829 is a drug associated with $89,047 in payments to 0 healthcare providers, recorded across 53 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2019. In 2019, $84,991 was paid across 41 transactions to 0 doctors.
The most common payment nature for GZ419829 is "Unspecified" ($89,047, 100.0% of total).
GZ419829 is associated with 5 research studies, including "A Prospective Safety Sub-Registry to Assess Anaphylaxis and Severe Allergic Reactions, and Severe Cutaneous and Systemic Immune Complex Mediated Reactions With Alglucosidase Alfa Treatment" ($71,112).